Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2021 May 17;3(2):zcab018. doi: 10.1093/narcan/zcab018

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2021. Published by Oxford University Press on behalf of NAR Cancer.

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.

PMC Copyright notice

Figure 1. — IDH1 mutation confers sensitivity to ATR inhibitors. (A–C) Five-day short-term cell viability assays of four separate ATR inhibitors AZD6738, ATRIN175, VE-822 and BAY-1895344. U87 (WT and IDH1 R132H/+), HCT116 (WT and IDH1 R132H/+) and LN229 (WT and doxycycline inducible IDH1 R132H/+) cells were used for this assay. (D) IC⁵⁰ ratios of screened WT and the IDH1 mutant cells indicate that the IDH1 mutant cells are more sensitive to all the four ATR inhibitors tested. (E) HCT116 WT and R132H/+ cells were treated with AZD6738 for 14 days (n = 6). Error bars represent means ± SEM, *P < 0.05.